Please use this identifier to cite or link to this item:
Title: Discovery of Chiral Cyclopropyl Dihydro-Alkylthio-Benzyl-Oxopyrimidine (S-DABO) Derivatives as Potent HIV-1 Reverse Transcriptase Inhibitors with High Activity Against Clinically Relevant Mutants
Authors: Botta, Maurizio 
Maga, G
Alongi, M
Angeli, L
Samuele, A
Zanoli, S
Bellucci, L
Tafi, Andrea 
Casaluce, G
Giorgi, Gianluca 
Armand Ugon, M
Gonzalez, E
Esté, Ja
Baltzinger, M
Bec, G
Dumas, P
Ennifar, E
Botta, Maurizio 
Issue Date: 2009
Project: None 
The role played by stereochemistry in the C2-substituent (left part) on the S-DABO scaffold for anti-HIV-1 activity has been investigated for the first time. A series of S-DABO analogues, where the double bond in the C2-substituent is replaced by an enantiopure isosteric cyclopropyl moiety, has been synthesized, leading to the identification of a potent lead compound endowed with picomolar activity against RT (wt) and nanomolar activity against selected drug-resistant mutants. Molecular modeling calculation, enzymatic studies, and surface plasmon resonance experiments allowed us to rationalize the biological behavior of the synthesized compounds, which act as mixed-type inhibitors of HIV-1 RT K103N, with a preferential association to the enzyme-substrate complex. Taken together, our data show that the right combination of stereochemistry on the left and right parts (C6-substituent) of the S-DABO scaffold plays a key role in the inhibition of both wild-type and drug-resistant enzymes, especially the K103N mutant.
ISSN: 0022-2623
DOI: 10.1021/jm801330n
Appears in Collections:Publications

Show full item record

Page view(s)

Last Week
Last month
checked on Jan 19, 2022

Google ScholarTM



Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.